Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(04): 261
DOI: 10.1055/s-0040-1721178
Letter to the Editor

Gemcitabine in Recurrent Meningioma

Satvik Khaddar
1   Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Arti Bhelekar
1   Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Ochin Dale
1   Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Litty Varghese
1   Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
,
Vijay Maruti Patil
1   Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
› Author Affiliations FundingNone.
› Further Information
Also available at
   Permissions and Reprints
Zoom Image
Dr Vijay M. Patil


Publication History

Article published online:
15 June 2021

© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Euskirchen P, Peyre M. Management of meningioma. Presse Med 2018; 47 (11-12 Pt 2) e245-e252
    CrossrefPubMedGoogle Scholar
  • 2 Kaley T, Barani I, Chamberlain M. et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-oncol 2014; 16 (06) 829-840
    CrossrefPubMedGoogle Scholar
  • 3 Sioka C, Kyritsis AP. Chemotherapy, hormonal therapy, and immunotherapy for recurrent meningiomas. J Neurooncol 2009; 92 (01) 1-6
    CrossrefPubMedGoogle Scholar
  • 4 Takeda H, Okada M, Kuramoto K. et al. Antitumor activity of gemcitabine against high-grade meningioma in vitro and in vivo. Oncotarget 2017; 8 (53) 90996-91008
    CrossrefPubMedGoogle Scholar